Company: DVAX
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0001029142-25-000049
Chunk: 131

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-02-20
Form: 10-K
Item: Item 7
Chunk 131
---
 percentages):

Year Ended December 31,Increase (Decrease) from 2023 to 2024Program Expenses:20242023$%Shingles19,880 14,252 5,628 39 %Tdap4,121 6,620 (2,499)(38)%Plague (1)4,020 8,319 (4,299)(52 %)HEPLISAV-B and CpG 1018 adjuvant development5,183 5,626 (443)(8 %)Other13,759 8,210 5,549 68 %Other Research and Development Expenses:Facility costs2,738 2,574 164 6 %Non-cash stock-based compensation11,849 9,285 2,564 28 %Total research and development$61,550 $54,886 $6,664 12 %

(1)In September 2021, we entered into an agreement with the DoD for the development of a recombinant plague vaccine utilizing CpG 1018 adjuvant. Under the agreement, we conducted a Phase 2 clinical trial and studies combining our CpG 1018 adjuvant with the DoD's rF1V vaccine. We are being fully reimbursed by the DoD for the costs of this study which is recorded in other revenue in our consolidated statements of operations.

Research and development expenses increased by $6.7 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. 

•Shingles program costs increased primarily due to increased clinical expenses related to the initiation of a Phase 1/2 clinical trial and the completion of patient enrollment in the study in the fourth quarter of 2024.

•Tdap program costs decreased, as we completed the long-term Phase 1 extension study in the third quarter of 2024. In connection with the discontinued development of the Tdap-1018 program announced in November 2024, we do not expect to incur significant research and development expenses for this program in the future.

•Plague program costs decreased with the completion of the Phase 2 clinical trial in the third quarter of 2024, as compared to higher costs incurred in early 2023 due to the initiation of Part 2 of the Phase 2 clinical trial.

•HEPLISAV-B and CpG 1018 adjuvant development costs decreased due